Cannabinoid-profiled agents improve cell survival via reduction of oxidative stress and inflammation, and Nrf2 activation in a toxic model combining hyperglycemia+A beta(1-42) peptide in rat hippocampal neurons

Elmazoglu Z., Rangel-Lopez E., Noel Medina-Campos O., Pedraza-Chaverri J., Tunez I., Aschner M., ...Daha Fazla

NEUROCHEMISTRY INTERNATIONAL, cilt.140, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 140
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.neuint.2020.104817
  • Dergi Adı: NEUROCHEMISTRY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: Hyperglycemia, Amyloid beta peptide, Oxidative damage, Neuroinflammation, Cannabinoids, Neuroprotection, AMYLOID-BETA-PEPTIDE, ALZHEIMERS-DISEASE, HIGH GLUCOSE, MITOCHONDRIAL DYSFUNCTION, DIABETES-MELLITUS, IN-VITRO, RECEPTOR, CB1, DAMAGE, EXPRESSION
  • Gazi Üniversitesi Adresli: Evet

Özet

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder linked to various converging toxic mechanisms. Evidence suggests that hyperglycemia induces oxidative stress, mitochondrial dysfunction, inflammation and excitotoxicity, all of which play important roles in the onset and progression of AD pathogenesis. The endocannabinoid system (ECS) orchestrates major physiological responses, including neuronal plasticity, neuroprotection, and redox homeostasis, to name a few. The multi-targeted effectiveness of the ECS emerges as a potential approach to treat AD. Here we characterized the protective properties of the endocannabinoids arachidonylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), the synthetic cannabinoids CP 55-940 and WIN 55,212-2, and the fatty acid amide hydrolase (FAAH) inhibitor URB597, on a combined hyperglycemia + oligomeric amyloid beta peptide (A beta(1-42)) neurotoxic model in primary hippocampal neurons which exhibit several AD features. Cells were treated with cannabinoid agents at increased concentrations (1 nM-1 mu M) for 6 h, and then co-treated with 150 mM glucose (GLU, 24 h), followed by incubation with 500 nM A beta(1-42) (24 h). Cell viability/survival, reactive oxygen species (ROS) levels, antioxidant enzyme (SOD, CAT, GPx and GRx) activities, biological products of oxidative damage (AGE and HNE adducts) and nitrosative stress (3-NT), several endpoints of inflammation (iNOS, IL-1 beta and TNF-alpha), amyloid quantification, mitochondrial membrane potential, and the involvement of the Nrf2 pathway, were all evaluated. The combined high glucose + amyloid beta 1-42 (GLU + A beta(1-42)) condition decreased cell viability and mitochondrial membrane potential, while augmenting oxidative damage and inflammation. All agents tested preserved cell viability and stimulated mitochondrial membrane potential, while reducing all the evaluated toxic endpoints in a differential manner, with URB597 showing the highest efficacy. The neuroprotective efficacy of all cannabinoid agents, except for URB597, led to partial recruitment of specific antioxidant activity and Nrf2 pathway regulation. Our results support the neuroprotective potential of these agents at low concentrations against the damaging effects of GLU + A beta(1-42), affording new potential modalities for the design of AD therapies.